Skip to main content
Premium Trial:

Request an Annual Quote

Signature Bioscience Raises $43M in Fourth Round of Financing

NEW YORK, July 9 - Signature Bioscience has completed its fourth round of financing, raising $43 million in a private placement, the company said Monday.

The company said it will use the money to expand into drug discovery by acquiring drug targets and chemical libraries, to support the company's technology platform, and to potentially acquire other businesses that may complement the company's push into drug development. The company's technology is centered around a technique called Multipole Coupling Spectroscopy, which uses radio frequency waves to probe protein structure and drug-protein interactions.

New investors in the fourth round of financing included SG Capital Partners, Vulcan Ventures, MDS Capital Group, China Development Industrial Bank, Tallwood Venture Capital, Lehman Brothers, Lotus Bioscience Ventures, and IRR. With the help of current investors Prospect Venture Partners, and others, the company has so far raised a total of $64 million in venture capital funding since the company was founded in 1998.

"In today's tight fundraising climate, this new infusion of capital by a world-class group of investors is strong validation of the strength of our technology, business plan, and vision of quickly evolving from an instrument platform into a broad-based discovery company employing the power of our novel multipole coupling spectroscopy," Mark McDade, Signature's CEO, said in a statement.  
The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.